Gender-specific Survival Following Radical Cystectomy for PT4 Bladder Cancer
Overview
Authors
Affiliations
Purpose: To evaluate the association of gender with survival following radical cystectomy (RC) for patients with pT4 bladder cancer.
Materials And Methods: We reviewed our institutional registry of 2,088 patients treated with RC between 1980 and 2005 to identify 128 with pT4 tumors, including 91 males and 37 females. Survival was estimated using the Kaplan-Meier method and compared with log-rank test. Cox hazard regression models were used to analyze the association of clinicopathologic demographics, including gender, with outcome.
Results: A total of 7 women and 30 men with pT4 tumor received perioperative chemotherapy. Median postoperative follow-up was 10.5 years, during which time 27 patients experienced local recurrence (LR) and 120 died, including 90 who died from bladder cancer. Women with pT4 tumor trended to have higher 5-year LR-free survival (72 vs. 59 %; p = 0.83), cancer-specific survival (31 vs. 17 %; p = 0.50), and overall survival (19 vs. 11 %; p = 0.33), although these differences did not reach statistical significance. On multivariate analysis, moreover, gender was not significantly associated with LR (HR 0.96; p = 0.93), cancer-specific mortality (HR 1.05; p = 0.87), or all-cause mortality (ACM) (HR 1.14; p = 0.58). Instead, poor ECOG performance status and pN+ disease were associated with an increased risk of ACM, while removal of a greater number of lymph nodes was associated with decreased ACM.
Conclusion: We did not find gender-specific disparities in survival following RC for pT4 bladder cancer. Prognosis was instead driven by patient performance status and lymph node status.
Sexual dimorphism in bladder cancer: a review of etiology, biology, diagnosis, and outcomes.
Zhu S, Zhao H Front Pharmacol. 2024; 14:1326627.
PMID: 38283839 PMC: 10811034. DOI: 10.3389/fphar.2023.1326627.
Prediction of locally advanced bladder tumor using preoperative clinical parameters.
Mirsya Warli S, Febrian Prapiska F, Siregar D, Wijaya W Urol Ann. 2023; 15(4):412-416.
PMID: 38074177 PMC: 10699183. DOI: 10.4103/ua.ua_1_23.
Moorthy H, Laxman Prabhu G, Venugopal P Indian J Urol. 2020; 36(3):171-178.
PMID: 33082631 PMC: 7531383. DOI: 10.4103/iju.IJU_320_19.
Jun I, Kim J, Kim H, Koh G, Hwang J, Kim Y Sci Rep. 2019; 9(1):14096.
PMID: 31575918 PMC: 6773750. DOI: 10.1038/s41598-019-50582-6.
Zhang L, Wu B, Zha Z, Qu W, Zhao H, Yuan J BMC Cancer. 2019; 19(1):716.
PMID: 31324162 PMC: 6642549. DOI: 10.1186/s12885-019-5924-6.